TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9356093

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 201

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 201
Study: 8411294

Group type: EXPERIMENTAL
Intervention: Standard auricular acupuncture treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham treatment (geographically close points)
Number of subjects: 100
Study: 3092937

Group type: EXPERIMENTAL
Intervention: Sulphinpyrazone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31895658

Group type: EXPERIMENTAL
Intervention: Marine n-3 fatty acids (1 g/d)
Number of subjects: 25871

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d)
Number of subjects: 25871
Study: 29530933

Group type: EXPERIMENTAL
Intervention: Trastuzumab (1 or 2 years; N = 561)
Number of subjects: 862

Group type: COMPARATOR
Intervention: Observation (N = 301)
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: Cyclin D1 (as continuous variable)
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: TOP2A, Ki67, and cyclin D1 (as categorical variables)
Number of subjects: 862
Study: 27069071

Group type: EXPERIMENTAL
Intervention: 10 sessions of manualized family intervention
Number of subjects: 620

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: 6 sessions of manualized family intervention
Number of subjects: 620
Study: 24973609

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 42
Study: 22352443

Group type: EXPERIMENTAL
Intervention: Blood Loss Scores derived from the first group (n = 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Blood Loss Scores validated against the second group (n = 50)
Number of subjects: 100
Study: 19853420

Group type: EXPERIMENTAL
Intervention: F2 colloidal nanosuspension (EUD RS 100)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: F5 colloidal nanosuspension (EUD RL 100)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zovirax (commercial product)
Number of subjects: 0
Study: 17487633

Group type: EXPERIMENTAL
Intervention: Provision of a financial incentive
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduction of logistical barriers
Number of subjects: 0
Study: 15784492

Group type: EXPERIMENTAL
Intervention: Intravenous supplementary nutrition (1000 kcal/day for 3 days, followed by oral supplementary nutrition (400 kcal/day for 7 days))
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ordinary hospital food and beverage (Control group)
Number of subjects: 80
Study: 11897546

Group type: EXPERIMENTAL
Intervention: 20% human albumin 50 ml
Number of subjects: 20

Group type: COMPARATOR
Intervention: Furosemide 40 mg
Number of subjects: 20
Study: 10483385

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7916403

Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (1 MU) with hepatitis B vaccine (20 micrograms)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo with hepatitis B vaccine (20 micrograms)
Number of subjects: 52
Study: 2802121

Group type: EXPERIMENTAL
Intervention: Supraclavicular brachial plexus block with prilocaine 1% and bupivacaine 0.5%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supraclavicular brachial plexus block with prilocaine 1% and discrete nerve blocks with bupivacaine 0.5%
Number of subjects: 80
Study: 1148090

Group type: EXPERIMENTAL
Intervention: Propanidid and lignocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methohexitone and suxamethonium
Number of subjects: 0
Study: 31033364

Group type: EXPERIMENTAL
Intervention: Naproxen 220-750 mg/day
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 1494
Study: 28821469

Group type: EXPERIMENTAL
Intervention: Athletic coach-delivered ARA/SV prevention program
Number of subjects: 973
Study: 26722699

Group type: EXPERIMENTAL
Intervention: Oral health training for care-staff
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Scaled up oral health training for all staff
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Second training cycle including all staff
Number of subjects: 162

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 162
Study: 23128815

Group type: EXPERIMENTAL
Intervention: Sonothrombolysis using 2 diagnostic probes and bilateral monitoring
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard sonothrombolysis
Number of subjects: 12
Study: 22314690

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4% lidocaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 20594330

Group type: EXPERIMENTAL
Intervention: Exercise (Ex)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-exercise (NEx)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups (Ex and NEx)
Number of subjects: 31
Study: 17944889

Group type: EXPERIMENTAL
Intervention: Banxia houpu tang (BHT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 104
Study: 15857739

Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 523
Study: 12160514

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9477056

Group type: EXPERIMENTAL
Intervention: 5-45 microg intrathecal fentanyl
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 25 microg intrathecal fentanyl
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl
Number of subjects: 84
Study: 7890075

Group type: EXPERIMENTAL
Intervention: Synchronized administration of hCG at the onset of the endogenous LH rise (J group)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Non-synchronized administration of hCG (non-J group)
Number of subjects: 148
Study: 1854108

Group type: EXPERIMENTAL
Intervention: Aminophylline (loading dose followed by routine infusion, n = 65)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo (equal volume as loading dose and infusion, n = 68)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Aminophylline (n = 65)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo (n = 68)
Number of subjects: 133
Study: 6661511

Group type: EXPERIMENTAL
Intervention: Medroxalol solution (100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Medroxalol tablet formulation (100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Medroxalol intravenous (100 mg)
Number of subjects: 10
Study: 31770771

Group type: EXPERIMENTAL
Intervention: Participants reported the Gabor orientation while ignoring the vowel sound (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants attended to both modalities (Experiments 2 and 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous stimulus alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No-response trials interleaved (Experiment 3)
Number of subjects: 0
Study: 27687644

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard Care (Control)
Number of subjects: 42
Study: 27256183

Group type: EXPERIMENTAL
Intervention: Retropubic prostatectomy (RP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Suprapubic prostatectomy (SP)
Number of subjects: 65
Study: 26954517

Group type: EXPERIMENTAL
Intervention: Rapid testing (VIKIA-HBsAg/Quick Profile anti-HBsAb) with confirmatory serology (R+S)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Standard serology (S)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Rapid testing (VIKIA-HBsAg)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Anti-HBsAb Quick Profile rapid test
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Rapid testing (R+S)
Number of subjects: 409
Study: 23915701

Group type: EXPERIMENTAL
Intervention: Radial free forearm flap
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nasolabial flap
Number of subjects: 50
Study: 22137512

Group type: EXPERIMENTAL
Intervention: Double-lumen tube (DLT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Classic endotracheal tube (ETT)
Number of subjects: 75
Study: 19882577

Group type: EXPERIMENTAL
Intervention: Biaxial microincision surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Coaxial small incision cataract surgery
Number of subjects: 70
Study: 17078772

Group type: EXPERIMENTAL
Intervention: Water heated to 42 degrees C
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control water condition (temperature of the warmest limbs)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control and warm water conditions
Number of subjects: 11
Study: 15037490

Group type: COMPARATOR
Intervention: Light to moderate alcohol consumption (monthly, weekly, daily)
Number of subjects: 14125

Group type: COMPARATOR
Intervention: Light to moderate alcohol consumption (monthly, weekly, daily) among men with systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg
Number of subjects: 14125

Group type: COMPARATOR
Intervention: Moderate alcohol consumption
Number of subjects: 14125
Study: 11709512

Group type: EXPERIMENTAL
Intervention: Balsalazide 3.0 g twice daily
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Balsalazide 1.5 g twice daily
Number of subjects: 133

Group type: COMPARATOR
Intervention: Mesalazine 0.5 g three times daily
Number of subjects: 133
Study: 9473880

Group type: EXPERIMENTAL
Intervention: Individual, focused breast‐feeding counselling
Number of subjects: 161

Group type: COMPARATOR
Intervention: Routine advice for diarrhoea (Control)
Number of subjects: 161
Study: 8561442

Group type: EXPERIMENTAL
Intervention: verapamil LI 120 mg 3 times a day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: verapamil LP 120 mg twice a day
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 2122015

Group type: EXPERIMENTAL
Intervention: Biosynthetic human growth hormone (BSHGH) 0.1 mg/kg/day for 7 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Biosynthetic human growth hormone (BSHGH)
Number of subjects: 15
Study: 225956

Group type: COMPARATOR
Intervention: Condition A (no external limb resistance)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Condition B (3.1 Kg of premovement limb resistance)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Condition C (9.8 Kg of premovement limb resistance)
Number of subjects: 12
Study: 30269273

Group type: EXPERIMENTAL
Intervention: MR training in 3rd year preschoolers
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: MR training in 1st year preschoolers
Number of subjects: 2

Group type: COMPARATOR
Intervention: Comparison of training effects between 1st and 3rd year preschoolers
Number of subjects: 2
Study: 31410893

Group type: EXPERIMENTAL
Intervention: Conventional denture (CD)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fixed prosthesis (FP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Milled bar overdenture (MB)
Number of subjects: 16
Study: 27596805

Group type: EXPERIMENTAL
Intervention: Digital scanning (TRIOS Pod)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional impression (open tray with elastomer)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Digital scanning (TRIOS Pod) and Conventional impression (open tray with elastomer)
Number of subjects: 100
Study: 26017816

Group type: EXPERIMENTAL
Intervention: Automated-counseling website
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard educational website
Number of subjects: 98
Study: 24409806

Group type: EXPERIMENTAL
Intervention: Arthroscopic, minimally invasive percutaneous plate osteosynthesis (MIPPO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Modified plate fixation
Number of subjects: 40
Study: 21834489

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg + atorvastatin 10 mg
Number of subjects: 93

Group type: COMPARATOR
Intervention: atorvastatin 20 mg + placebo
Number of subjects: 93
Study: 19858392

Group type: EXPERIMENTAL
Intervention: Yttrium-90 ibritumomab tiuxetan
Number of subjects: 414

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 414
Study: 16766978

Group type: EXPERIMENTAL
Intervention: Tutoplast-cancellous-chips (allograft)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Iliac crest bone grafting (autologous)
Number of subjects: 90
Study: 15729016

Group type: EXPERIMENTAL
Intervention: Cefaclor 50 mg/kg/day for 5 days
Number of subjects: 410

Group type: COMPARATOR
Intervention: Cefaclor 40 mg/kg/day for 10 days
Number of subjects: 410
Study: 11791125

Group type: EXPERIMENTAL
Intervention: Anthracycline-containing polychemotherapy regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimens containing epirubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epirubicin-taxane combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study: 9210991

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Guided mastery therapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Pre-treatment depression
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Interpersonal problems at pre-treatment
Number of subjects: 46
Study: 8353046

Group type: EXPERIMENTAL
Intervention: Low-dose recombinant interleukin-2 (rIL-2) at dose levels of 0.18, 0.6, 1.8, or 6 x 10(6) IU m-2 24 h-1; one patient treated with 3 x 10(6) IU m-2 24 h-1
Number of subjects: 13
Study: 2297142

Group type: EXPERIMENTAL
Intervention: Active treatment with oral immunotherapy (Artemisia pollen extract) over a 50-day course, cumulative dose of 396,652 PNU
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 268377

Group type: EXPERIMENTAL
Intervention: 1 APF tablet containing 1 mg fluoride
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: 2 APF tablets (3 hours apart) each school day
Number of subjects: 338

Group type: COMPARATOR
Intervention: 1 placebo tablet
Number of subjects: 338
Study: 31782864

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 41

Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both diclofenac and tramadol
Number of subjects: 41
Study: 31554360

Group type: EXPERIMENTAL
Intervention: HDR brachytherapy with concurrent chemotherapy (Paclitaxel and Carboplatin)
Number of subjects: 29

Group type: COMPARATOR
Intervention: HDR brachytherapy alone (standard of care arm)
Number of subjects: 29
Study: 28292489

Group type: EXPERIMENTAL
Intervention: Nurse-based case management intervention
Number of subjects: 0
Study: 25801652

Group type: EXPERIMENTAL
Intervention: TV005
Number of subjects: 168

Group type: COMPARATOR
Intervention: TV003
Number of subjects: 168
Study: 24288948

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (1 g/day for 3 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (for 3 months)
Number of subjects: 40
Study: 21696241

Group type: EXPERIMENTAL
Intervention: Adolescent Impact intervention (n = 83)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard of care (n = 83)
Number of subjects: 166
Study: 19419355

Group type: EXPERIMENTAL
Intervention: NTS+MMG (Non-Technical Skills + Medical Management Group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: MMG (Medical Management Group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: NTS+MMG
Number of subjects: 42

Group type: COMPARATOR
Intervention: MMG
Number of subjects: 42
Study: 16409457

Group type: EXPERIMENTAL
Intervention: High-dose antithrombin (AT)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study: 15575918

Group type: EXPERIMENTAL
Intervention: Everolimus (1.5 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus (3 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azathioprine (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus (TDM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study: 11728044

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 592
Study: 9457582

Group type: EXPERIMENTAL
Intervention: Hypothenar fat pad flap modified closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard closure
Number of subjects: 0
Study: 8493292

Group type: EXPERIMENTAL
Intervention: Late Sleep Deprivation (LSD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Early Sleep Deprivation (ESD)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hormonal levels (thyroid stimulating hormone, free triiodothyronine, prolactin, cortisol)
Number of subjects: 26
Study: 2942050

Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin 10 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin 20 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo injection of saline
Number of subjects: 36
Study: 31228560

Group type: EXPERIMENTAL
Intervention: High School Transition Program (HSTP) intervention (n=247)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Control group (n=233)
Number of subjects: 497
Study: 29676972

Group type: EXPERIMENTAL
Intervention: Alumina air abrasion with 50‐μm alumina particles and Scotchbond Universal/RelyX Unicem 2 (Al-SU)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alumina air abrasion with 50‐μm alumina particles and Z‐Prime Plus/Duo‐link Universal (Al-ZP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alumina air abrasion with 50‐μm alumina particles and Monobond Plus/Variolink II (Al-MB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Scotchbond Universal/RelyX Unicem 2 without air abrasion (SU)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alumina air abrasion with 50‐μm alumina particles and Alloy Primer/ED Primer II/Panavia F 2.0 (Al-AP)
Number of subjects: 80
Study: 27261936

Group type: EXPERIMENTAL
Intervention: Topical lidocaine (3 mg/kg body weight)
Number of subjects: 13
Study: 25029008

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) 2 g/day for 28 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (PL) 2 g/day for 28 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 41
Study: 22659999

Group type: EXPERIMENTAL
Intervention: Vitamin B‐12 (500 µg/day) for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 20689153

Group type: EXPERIMENTAL
Intervention: Full-Defusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial-Defusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full-Distraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial-Distraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distraction-based experimental control task
Number of subjects: 0
Study: 19021036

Group type: EXPERIMENTAL
Intervention: Various innovative and culturally specific interventions targeting children's lifestyle behaviors
Number of subjects: 28
Study: 16171665

Group type: EXPERIMENTAL
Intervention: Tramadol 1.5 mg/kg IV followed by continuous infusion of 0.5 mg/kg per hour until the end of surgery (group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: IV normal saline (group II)
Number of subjects: 40
Study: 12854475

Group type: EXPERIMENTAL
Intervention: 2 mg.kg-1 propofol (group P2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1 mg.kg-1 propofol (group P1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intralipid 0.2 ml.kg-1 (group C)
Number of subjects: 90
Study: 9884384

Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isoproterenol (before NG‐monomethyl‐L‐arginine)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isoproterenol (after NG‐monomethyl‐L‐arginine)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Forearm ischemia
Number of subjects: 36
Study: 8559420

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 1651071

Group type: EXPERIMENTAL
Intervention: Topical application of 13‐cis‐retinoic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of all‐trans‐retinoic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of arotinoid methyl sulphone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of arotinoid ethyl sulphone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo creams
Number of subjects: 0
Study: 6352603

Group type: EXPERIMENTAL
Intervention: Azlocillin (group I) at mean dosage of 252 mg/kg/day for a mean duration of 13.2 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Carbenicillin (group II) at mean dosage of 505 mg/kg/day for a median duration of 12.6 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Azlocillin (group I)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Carbenicillin (group II)
Number of subjects: 26
Study: 31111060

Group type: EXPERIMENTAL
Intervention: LED phototherapy
Number of subjects: 166

Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 166
Study: 26575606

Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 10050

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 10050

Group type: EXPERIMENTAL
Intervention: Insulin use
Number of subjects: 10050

Group type: EXPERIMENTAL
Intervention: Progression from prediabetes to diabetes
Number of subjects: 10050

Group type: EXPERIMENTAL
Intervention: Insulin treatment initiation in overt diabetes
Number of subjects: 10050

Group type: EXPERIMENTAL
Intervention: Years lived without glucose impairment
Number of subjects: 10050
Study: 24283587

Group type: EXPERIMENTAL
Intervention: Catheter-free method
Number of subjects: 93

Group type: COMPARATOR
Intervention: Catheter-insertion method
Number of subjects: 93
Study: 21691841

Group type: EXPERIMENTAL
Intervention: Prepaid cash incentive ($2)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: High lottery (2 prizes of $250)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Prepaid cash
Number of subjects: 3000